"Bear I am not exactly sure. But is Resverlogix able to patent an SGLT2 brand name ( i.e. Invokana) with ABL without obtaining permission from Janssen Pharma? For example RVX + (Generic) Rosuvastatin as was patented by Resverlogix."

Yes they can. They are patenting the combo, not the individual drug. In this way, Resverlogix is locking up the patent rights to a fixed dose combination pill containing both drugs. Way better for Resverlogix to file this combo pill patent as opposed to another company with SGLT2 inhibitor filing a similar patent before Resverlogix does. In this way, Resverlogix has the patent leverage on the combo and also the fixed dose combo is considered a new drug and hits the reset button on the patent timeline. Well played, Resverlogix, well played.

Resverlogix has probably filed similar patents for apabetalone in combo with DPP4 inhibitors and GLP-1 receptor agonists, with which Resverlogix has also dropped hints that there was synergy with apabetalone.

BDAZ